RecruitingPhase 1NCT06465069
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Sponsor: Eli Lilly and Company
Chicago, IL · +22 more sites
Breast Cancer clinical trials in Chicago, IL
43 recruiting breast cancer studies with a site in Chicago, IL.
RecruitingPhase 3NCT07391774
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Sponsor: National Cancer Institute (NCI)
Bloomington, IL · Canton, IL · Carterville, IL · +200 more sites
RecruitingPhase 1NCT06545331
Study of XB010 in Subjects With Solid Tumors
Sponsor: Exelixis
Chicago, IL · +15 more sites
RecruitingPhase 3NCT06841354
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Sponsor: Merck Sharp & Dohme LLC
Chicago, IL · +38 more sites
RecruitingPhase 1NCT07310420
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
Sponsor: TerSera Therapeutics LLC
Chicago, IL · Evanston, IL · Lisle, IL · +23 more sites
RecruitingPhase 3NCT07174336
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Sponsor: Eli Lilly and Company
Chicago, IL · +126 more sites
RecruitingPhase 1NCT06840886
A Study of PHST001 in Advanced Solid Tumors
Sponsor: Pheast Therapeutics
Chicago, IL · +19 more sites
RecruitingPhase 3NCT06982521
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Sponsor: Relay Therapeutics, Inc.
Chicago, IL · +50 more sites
RecruitingPhase 1NCT07454642
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Sponsor: Avacta Life Sciences Ltd
Chicago, IL · +6 more sites
RecruitingPhase 2NCT06172478
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Sponsor: Daiichi Sankyo
Chicago, IL · +12 more sites
RecruitingNot applicableNCT07553234
Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment
Sponsor: University of Chicago
Chicago, IL
RecruitingNot applicableNCT07214532
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Sponsor: Natera, Inc.
Chicago, IL · +48 more sites
RecruitingPhase 1NCT05983432
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Sponsor: SystImmune Inc.
Chicago, IL · +21 more sites
RecruitingPhase 3NCT06492616
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Sponsor: Stemline Therapeutics, Inc.
Arlington Heights, IL · Chicago, IL · +173 more sites
RecruitingPhase 2NCT04886531
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Sponsor: Ruth O'Regan
Chicago, IL · +3 more sites
RecruitingPhase 3NCT05879926
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor: NRG Oncology
Alton, IL · Aurora, IL · +1223 more sites
RecruitingPhase 3NCT06072612
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Sponsor: BriaCell Therapeutics Corporation
Chicago, IL · Springfield, IL · Urbana, IL · +76 more sites
RecruitingPhase 3NCT05232916
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Sponsor: Greenwich LifeSciences, Inc.
Chicago, IL · Zion, IL · +49 more sites
RecruitingPhase 3NCT05812807
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Sponsor: Alliance for Clinical Trials in Oncology
Aurora, IL · Barrington, IL · +825 more sites
RecruitingPhase 3NCT06748222
E-Mindfulness Approaches for Living After Breast Cancer
Sponsor: NRG Oncology
Arlington Heights, IL · Aurora, IL · Bloomington, IL · +378 more sites
RecruitingPhase 2NCT06184750
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
Sponsor: National Cancer Institute (NCI)
Chicago, IL · +9 more sites
RecruitingPhase 2NCT05467891
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Sponsor: Oana Danciu
Chicago, IL · +20 more sites
RecruitingPhase not listedNCT06551116
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
Sponsor: Abramson Cancer Center at Penn Medicine
Chicago, IL · New Lenox, IL · Orland Park, IL · +34 more sites
RecruitingPhase 4NCT06169371
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
Sponsor: University of Illinois at Chicago
Chicago, IL · +2 more sites
RecruitingPhase 1NCT04389632
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Calumet City, IL · Chicago, IL · +103 more sites
RecruitingPhase 1NCT07046923
A Study of LY4175408 in Participants With Advanced Cancer
Sponsor: Eli Lilly and Company
Chicago, IL · +14 more sites
RecruitingPhase 1NCT05283330
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Sponsor: Orano Med Theranostics, SAS
Chicago, IL · +7 more sites
RecruitingPhase 2NCT04434040
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Sponsor: Dana-Farber Cancer Institute
Chicago, IL · New Lenox, IL · Orland Park, IL · +4 more sites
RecruitingNot applicableNCT07387445
Feasibility and Acceptibility of a Multi-site Trial of Time Restircted Eating During Chemotheraply for Breast Cancer.
Sponsor: University of Illinois at Chicago
Chicago, IL
RecruitingPhase 3NCT04852887
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Sponsor: NRG Oncology
Alton, IL · Aurora, IL · +809 more sites
RecruitingPhase 1 / Phase 2NCT06395519
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Sponsor: 858 Therapeutics, Inc.
Chicago, IL · +13 more sites
RecruitingNot applicableNCT05483283
Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care
Sponsor: University of Illinois at Chicago
Chicago, IL
RecruitingPhase 2NCT06099769
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
Chicago, IL · +11 more sites
RecruitingPhase 1NCT06778863
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Sponsor: Clasp Therapeutics, Inc.
Chicago, IL · +20 more sites
RecruitingPhase 4NCT04373564
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Sponsor: Guerbet
Chicago, IL · Peoria, IL · +14 more sites
RecruitingPhase 3NCT05929768
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Sponsor: SWOG Cancer Research Network
Alton, IL · Aurora, IL · +952 more sites
RecruitingPhase not listedNCT00898131
Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer
Sponsor: Northwestern University
Chicago, IL
RecruitingNot applicableNCT05259410
Time Restricted Eating During Chemotherapy for Breast Cancer
Sponsor: University of Illinois at Chicago
Chicago, IL
RecruitingPhase 1NCT05216432
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Sponsor: Relay Therapeutics, Inc.
Chicago, IL · +23 more sites
RecruitingPhase 1NCT05107674
A Study of NX-1607 in Adults With Advanced Malignancies
Sponsor: Nurix Therapeutics, Inc.
Chicago, IL · +9 more sites
RecruitingNot applicableNCT04606030
LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)
Sponsor: Fibralign Corporation
Chicago, IL · +1 more sites
Not yet recruitingNot applicableNCT07840599
Fit2ThriveMB: Optimization of a Physical Activity Promotion Intervention for Metastatic Breast Cancer Patients
Sponsor: Northwestern University
Chicago, IL
Not yet recruitingPhase 3NCT07695948
Effects, Metabolic Mechanisms and Predictors of Response to Acupuncture in Treating Psychoneurological Symptoms Among Breast Cancer Survivors
Sponsor: University of Illinois at Chicago
Chicago, IL
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.